Financhill
Back

Treace Medical Concepts Quote, Financials, Valuation and Earnings

Treace Medical Concepts Price Quote

$8.29

Treace Medical Concepts Key Stats

Buy
57
Treace Medical Concepts (TMCI) is a Buy

Day range:
$7.87 - $8.49
52-week range:
$3.92 - $15.98
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
2.53
P/B ratio:
4.92%

Volume:
1.8M
Avg. volume:
695.4K
1-year change:
-6.54%
Market cap:
$516.4M
Revenue:
$187.1M
EPS:
$-0.99

How Much Does Treace Medical Concepts Make?

Is Treace Medical Concepts Growing As A Company?

Treace Medical Concepts Stock Price Performance

What Is Treace Medical Concepts 52-Week High & Low?

Treace Medical Concepts Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Treace Medical Concepts?

Is Treace Medical Concepts Cash Flow Positive?

  • What Is TMCI Cash Flow From Operations?
    Cash flow from operations (TTM) is -$32.4M
  • What Is Treace Medical Concepts’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $299K
  • What Is Treace Medical Concepts’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $37M

Treace Medical Concepts Return On Invested Capital

  • Is Management Doing A Good Job?
    TMCI return on invested capital is -34.77%
  • What Is Treace Medical Concepts Return On Assets?
    ROA measures how assets are converting to revenues and is -26.2%
  • What Is TMCI Return On Equity?
    ROE is a measure of profitability and is -49.68%

Treace Medical Concepts Earnings Date & Stock Price

Treace Medical Concepts Competitors

Treace Medical Concepts Dividend Yield

Treace Medical Concepts Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 4.65%
Revenue: 10.62% 3.69%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 6
Sell Recommendations: 0
Price Target: 7.50
Downside from Last Price: -9.53%

Major Shareholders

  • How many TMCI shares are owned by institutional investors?
    60.5M TMCI shares are owned by institutional investors
  • How many TMCI shares are owned by insiders?
    10.8M TMCI shares are owned by insiders